secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001104659-25-076412
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia reports Q2 2025 results: YUTREPIA launch drives $6.5M product revenue, net loss widens
--------------------------------------------------------------------------------

- YUTREPIA (treprostinil) inhalation powder approved by FDA May 23, 2025; commercial launch in June 2025.
- Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval.
- ASCENT trial interim: median 6MWD improvement 31.5m at Week 16; median dose 159 mcg QID; no drug-related discontinuations.
- Cash $173.4M as of June 30, 2025; product revenue $6.5M in Q2 2025 (first YUTREPIA sales).
- Net loss $41.6M ($0.49 per share) vs $28.7M ($0.38) in Q2 2024; SG&A up 95% on commercialization and litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925076412/0001104659-25-076412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925076412/tm2523179d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer